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Abstract: Cylindrospermopsin (CYN) is a naturally occurring alkaloid produced by a variety of 
cyanobacteria and known to induce oxidative stress-mediated toxicity in eukaryotic cells. 
Despite extensive research on the mechanism of CYN toxicity, an understanding of the 
structural features responsible for this toxicity and the mechanism by which it can enter the cell 
are still not clear. It was established that the presence of both the uracil and guanidine groups is 
essential in biological activity of CYN while not much is known in this regard on the role of tether 
that separates them and the attached hydroxyl group. Therefore, in the present study we have 
prepared three synthetic analogues possessing uracil and guanidine groups separated by a 
variable length tether (4-6 carbons) and containing a hydroxyl function in a position orientation 
to CYN, together with a tetracyclic analogue of CYN lacking the hydroxyl group at C-7. The 
toxicity of these compounds was then compared with CYN and guanidinoacetate (GAA; the 
primary substrate in CYN biosynthesis) in an in vitro model using human neutrophils isolated 
from healthy subjects. The lowest activity measured by means of reactive oxygen species 
generation, lipid peroxidation and cell death was observed for GAA and the tetracyclic 
analogue. The greatest toxicity was found in an analogue with a 6-carbon tether, but all three 
analogues and CYN caused rapid onset of redox imbalance. These results add to the general 
understanding of CYN toxicity and preliminary suggest that the -OH group at C-7 may be 
significant for the cellular transport of CYN and/or be involved in its toxic activity inside the cell, 
a hypothesis which requires further testing.   
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Introduction 
Cylindrospermopsin (CYN) 1, is a naturally occurring cyanotoxin originating from the 
cyanobacteria Cylindrospermopsis raciborskii.1 This was the first member of a small group of 
related alkaloids to be isolated, along with 7-epi-cylindrospermopsin 2, 7-deoxy-
cylindrospermopsin 3, 7-deoxy-desulfo-cylindrospermopsin 4 and 7-deoxy-desulfo-12-
acetylcylindrospermopsin 5 from this and other cyanobacteria species.2-4 In 1979 a bloom of C. 
raciborskii occurred and contaminated a local water supply and was thought to be responsible 
for an outbreak of hepatoenteritis in 1979.5 The outbreak, coined the “Palm Island mystery 
disease” was responsible for the hospitalization of 148 people, the vast majority children.5 The 
highly toxic potencies of CYN in different types of mammalian cells were later extensively 
demonstrated.6 Over ten freshwater species are currently known to be able to produce 1 
including Aphanizomenon ovalisporum, Raphidiopsis curvata and terrestrial strain of 
Hormoscilla pringsheimii (Figure 1). 7,8,9,10 The reasons behind its production are yet to be fully 
elucidated though the toxin is known to be actively released from intact cells, to up-regulate 
alkaline phosphatase in sympatric phytoplankton and to contribute to allelopathic interactions.11   
 
F
igure 1: The cylindrospermopsin alkaloids 
 
Previous studies have attempted to link the activity of CYN 1 to specific functional groups 
within the molecule, most notably a study by Sukenik who proposed that the uracil group was 
partially responsible for its potent toxic activity, reasoning that there might be competitive or 
inhibitory binding to a catalytic site.12 Since this study, there have been only a small number of 
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reports on the synthesis of analogues of the cylindrospermopsin family, most probably due to 
their structural complexity. However, Runnegar et al.13 conducted a structure activity 
relationship investigation (SAR) utilising a series of simplified synthetic analogues of the natural 
products. Within this work the unsulfonated analogues ±6 and 7 were studied along with tricyclic 
analogue ±8. The simplified uracil analogue ±9 was also investigated, as was the bicyclic 
sulfonate analogue ±10, which lacks the uracil group (Figure 2).13 
 
 
Figure 2: Cylindrospermopsin analogues 
Initially, the toxicity of synthetic racemic CYN ±1 was compared to that of the 
stereoisomer 7-epi-cylindrospermopsin 2. The results obtained provided evidence to state that 
the exact stereochemistry of the hydroxyl group located at C-7 had little effect on the biological 
activity or transport of the toxin. Furthermore, a comparison of the activity of ±1 and 2 alongside 
the corresponding diols ±6 and 7 indicated that ±1 and ±6 both inhibit protein synthesis with 
almost identical IC50 values of 0.20 and 0.21 μM, whilst 7-epi-cylindrospermopsin 2 and diol ±6 
each depleted cell antioxidant glutathione by similar amounts. These results indicate that the 
sulfate group present within majority of the CYN alkaloids plays no appreciable role in either 
their biological activity or cellular uptake. Of the other compounds studied, the tricyclic analogue 
±8 demonstrated an inhibitory effect on protein synthesis but only at concentrations between 
500-1000 times greater than those of 1. Similarly analogues ±9 which lacks the guanidine 
functionality, and ±10 which lacks the uracil ring displayed no biological activity at 
concentrations between 800 and 2000 μM.13 From these results it was concluded, that the 
presence of both the uracil and guanidine groups are essential and that the guanidine must be 
contained in a lipophilic environment to enable any biological activity. Shaw also investigated 
the role of the hydroxyl group located at C-7. This was done by analysing the effect of 7-deoxy-
cylindrospermopsin 3 in four different mammalian cell lines, the results demonstrated that 3 
displays the same levels of toxicity as CYN 1. The levels of protein synthesis inhibition were 
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also similar, with IC50 values of 340 and 220 nM for 3 and 1 respectively.14 Williams et al. also 
determined that both toxins inhibit protein synthesis within one order of magnitude of each other 
and that both have a similar inhibitory effect on cell glutathione.15 However, in vivo comparison 
of both compounds revealed that 3 did not produce any toxic effects at levels exceeding the 
lethal concentrations established for 1.3 Recently it was suggested that exposure to CYN at 
environmentally relevant concentrations, has the potential to lead to a reduced ability to fight 
pathogens and therefore increasing susceptibility to potential infections.16,17 Further work in this 
area has sought to elucidate the sequence of events underlying CYN induced oxidative stress in 
human cells. The toxin has been shown to significantly increase levels of intracellular reactive 
oxygen species (ROS) and significantly suppresses the activation of superoxide dismutase 
(SOD) and catalase (CAT) whilst up-regulating glutathione peroxidase (GPx).18  
It is apparent that it is still unclear as to role of the uracil group in these alkaloids, 
particularly as to its role in transportation into the cell or if it also plays a key role in the in vitro 
activity. It is however apparent the sulfate group does not play a significant role in either the 
biological activity or the transport of the CYN alkaloids, but that the hydroxyl group does play a 
vital role, but the hydroxyl-stereochemistry does not seem to be a key factor in this activity.13,14 
With these observations in mind, we were motivated to prepare a series of analogues of 1 which 
contain the key guanidine, uracil and hydroxyl groups found in 1 separated by a tether. Our plan 
was to simplify the metabolites by removing the tricyclic ring system and obtaining the 
structures 11a-c which are separated by a variable length tether (n = 1-3) (Figure 3). We 
eventually compared the bioactive properties of 11a-c with CYN 1, a tetracyclic analogue 22 
and guanidinoacetate (GAA; a primary substrate of CYN in cyanobacterial biosynthesis 
pathway19). We used an in vitro human cell model to elucidate the potential role of tether length 




Figure 3: Proposal of the structure of analogues 11. 
 





The synthesis of the analogues 11a-c began with the known aldehyde 1220 which was 
treated with the corresponding acetylinic Grignard reagents 13a-c (n = 1-3) in THF to give the 
corresponding alcohols 14a-c in 55-75 % yield. Hydrogenation of these gave the alcohols 15a-c 
(79-100 % yield), which were acetylated using acetic anhydride in pyridine to give acetates 16a-
c (68-88 % yields) and then desilylated with TBAF to give the alcohols 17a-c (71-80 % yield). 
Alcohols 17a-c were reacted with N,N’,N’’-tri-Boc-guanidine 18 in the presence of DIAD and 
triphenylphosphine to give guanidines 19a-c. These were deprotected by refluxing in 0.5 M HCl 
to give the desired guanidinium salts 11a-c. Unfortunately, on deprotection, the guanidine 
groups underwent partial hydrolysis to the amines 20a-c which were inseparable from 
guanidines 11a-c. However, treatment of this mixture with 1H-pyrazole-1-carboxamidine 
hydrochloride 21 and DIPEA, followed by purification on Amberlite© CG-50 gave the desired 




Scheme 1: Synthesis of the analogues 11a-c. (i) 13a-c, EtMgBr in THF (1M), -78 °C, 2 h, 0 °C – rt, 16 h. then 
NH4Cl aq. n = 1, 75 %; n = 2, 71 % n = 3, 55 %. (ii) Pd/C (10%), EA, H2, 2 h. n = 1, 79 %, n = 2, 100 %, n = 3, 86 
%. (iii) Ac2O, pyridine, DMAP, CH2Cl2, rt, 1 h. n = 1, 68 %, n = 2, 74 %, n = 3, 88 %. (iv) TBAF (1M), THF, 0 °C - rt, 
2 h, n = 1, 80 %; n = 2, 74 %, n = 3, 71 %. (v) DIAD, PPh3, N,N’,N”-tri-Boc-guanidine 18, THF, rt 16 h. (vi) HCl (0.5 
M), 100 °C, 16 h. (vii) 1H-Pyrazole-1-carboxamidine hydrochloride 21, DIPEA, DMF, 24 h, then Amberlite© CG-50l; 
11a; n = 1, 54 %; 11b; n = 2, 12 %; 11c; n = 3, 23 % (over three steps). 
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Concomitant to the preparation of the tethered analogues described above we prepared 
a tetracyclic analogue 22 of 7-deoxy-cylindrospermopsin 3. The synthesis of 22 began with our 
previously prepared aldehyde 23 which was subjected to a tethered Biginelli condensation with 
the β-keto ester 24 using our previously reported conditions.21,22 Under these conditions it was 
possible to isolate the tetracyclic guanidine 25 in 19% yield, the relative stereochemistry of 
which was determined by 2D NOESY NMR. Deallylation/decarboxylation of 25 was achieved by 
treatment with Pd(PPh3)4, followed by reduction with NaBH3CN to give guanidine 26 in 75% 
yield. Again 2D NOESY NMR was used to determine the orientation of the newly introduced 
methine proton. Deprotection of the N-benzyl groups was achieved by treatment with BBr3 




Scheme 2: Preparation of analogue 22. reagents and conditions: (a) AcOH, 24 h; (b) Morpholine acetate, 24, 
Na2SO4, CF3CH2OH, 100 °C, 12 d, 19%; (c) Pd(PPh3)4, pyrollidine, THF-MeOH (1:1), 4 h; (d) NaBH3CN, AcOH-
MeOH (1:1), 0 °C to rt, 16 h, 75% (2 steps); (e) i) BBr3, Xylenes, 130 °C, 16h; ii) MeOH, rt, 16 h, 93%. 
 
The β-keto ester 24 required for the synthesis of 22 was prepared by condensation of 
N,N'-dibenzylurea 2723 with diethyl 1,3-acetonedicarboxylate 28 in the presence of p-TsOH, to 
give the benzyl protected pyrimidine ester 29 in 67 % yield. Saponification of 29 by treatment 
with ethanolic NaOH, gave the corresponding carboxylic acid 30 in 78 % yield. The desired β-
keto ester functionality was incorporated using CDI mediated coupling24 of 30 with Meldrum’s 





Scheme 2: preparation of analogue 24. (a) p-TsOH, 28, 4 Å MS, benzene, 4 d, 67%; (b) NaOH, EtOH, 0 °C to rt, 
5 d,  78%; (c), CDI, 31, THF, 50 °C, 16 h; (d) Allyl alcohol, 110 °C, 16 h, 75%. 
 
Toxicity studies 
The present study compared the toxicity of the synthetic CYN analogues (11a, 11b, 11c 
and 22), 1 and GAA in human-derived neutrophils in vitro. Neutrophils are the most abundant 
and chemo-sensitive type of leukocytes with a circulating half-life of only 6-8 h,25 previously 
shown to be a suitable in vitro model to evaluate the toxicity of cyanobacterial metabolites.26-28 
The employed model is rapid in contrast to those employing cell lines that usually require 
culturing and a longer assay time to allow for cell responses. Moreover, in contrast to numerous 
toxicological in vitro studies involving human cell lines, our experimental model used cells 
isolated from healthy donors, thereby taking into account individual variability and susceptibility 
and for this reason the observed effects may be more relevant in human risk assessment. This 
study is amongst those that highlight that toxicology in vitro can be used as a convenient tool to 
investigate the biological activity of synthetic toxin analogues, prepared in order to elucidate 
which structures may play a pivotal in the toxicity of the parent compound.  
 The first assay monitored the intracellular levels of ROS and was employed to directly 
evaluate the potential of tested compounds in altering the cellular redox balance. The assay is 
based on a fluorogenic cell permeant dye which is oxidized to fluorescent compound 
(dichlorofluorescein) in the presence of different ROS. The vast majority of cyanobacterial 
metabolites and other toxic compounds (e.g. tBHP used in our study as positive control) are 
known to trigger ROS generation above physiological levels.29-31 Increased ROS can lead to 
oxidative stress which overwhelms the ability of biological system to readily detoxify the reactive 
intermediates resulting in damage to cellular structures and the genetic information. 32 
 As shown, all the compounds tested, at concentration of 2.0 µg mL-1, had the ability to 
temporarily increase the intracellular ROS levels to different extents (Figure 4A), which is in 
contrast to tBHP which caused a gradual increase in ROS over the exposure time. All the CYN 
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analogues tested showed a peak-pattern effect on the redox balance with the greatest levels of 
ROS noted after 15 minutes after the exposure was initiated. The most significant increase was 
observed in the presence of 11a which amounted to 121.6% of the control level. A slightly lower 
effect was found for 1 (120.5% of control level) and 11c (119.1% of control level). Importantly, 
11a was the only compound that caused a statistically significant increase in ROS level after 
just 5 min of exposure, indicating the highest bioavailability of all tested compounds. After 1 h of 
exposure the ROS level remained significantly increased after exposure to 1, 11a and 11c. The 
lowest effect on neutrophils redox balance was observed for 22 and GAA (Figure 4A).  
 The kinetics of the increase in ROS levels may be determined by the toxic properties of 
the compound but potentially also by how rapidly the toxic compound is being taken up and 
metabolized by cells. The potential detrimental outcomes of elevated generation of ROS levels 
include DNA damage, protein modifications, lipid peroxidation, and necrotic or apoptotic cell 
death.32 In the present study the two latter effects were also assessed to determine whether 
potential change in ROS levels produced adverse effects or whether neutrophils had the ability 
to cope with them through adaptive responses.  
 Peroxidation of lipids was measured by means of the malondialdehyde (MDA) content. 
MDA levels were significantly increased following the 1 h exposure to 2 µg mL-1 of 1, 11a, 11b 
and 11c. The 11c compound caused its elevation by as much as 33.3% when compared to the 
negative control, at level similar to positive control (Figure 4B).  Peroxidation of lipids is a chain 
reaction which is initiated by the hydrogen abstraction or addition of an oxygen radical, resulting 
in the oxidative damage of polyunsaturated fatty acids. Increased lipid oxidation can decrease 
the membrane fluidity and the final products of peroxidation (predominantly MDA and 4-
hydroxy-2-nonenal) can induce genotoxicity, and cell death.33,34 Consistent with their ability to 
increase ROS and MDA levels, 1, 11a, 11b and 11c also reduced cell viability accordingly 
(Figure 4C). In summary, the ability of compounds 11a, 11b and 11c to elevate ROS levels 
correlated closely with an increase in lipid peroxidation and cell death. If one considers the 
short-term exposure model applied in this study, the magnitude of observed effects highlights 
the potentially fast bioavailability of the tested compounds and onset of effects on cellular level. 
It should however be stressed that the employed concentration is much above the maximal 
observed for 1 in aquatic environment (usually found in the range of 1–10 μg L-1, maximal 
reported concentration exceeded 500 μg L-1) 35 and concentrations lower by order(s) of 
magnitude may not produce such adverse effects. Nevertheless, in the present study, a 
concentration of 2.0 µg mL-1 was used intentionally to maximize the potential differences in 





Figure 4. Generation of intracellular ROS (A), lipid peroxidation (B) and cell survival (C) after 1 
h exposure to different CYN analogues (1, 11a-11c and 22), GAA and 10 µM tBHP (positive 
control) expressed as percentage of control. Bars represent mean ± SD from three independent 
experiments corresponding to three different donors (n = 3). Asterisks represent statistically 
significant difference to the control (* - p < 0.05; ** - p < 0.01; *** - p < 0.001; Wilcoxon signed-
rank test). 
 
 The general toxicity decreased in the following order: 11c > 11a > 1 > 11b > 22 > GAA. 
Since all of the CYN analogues tested contained guanidine and uracil, either group could be 
involved in generating the observed in vivo effects. The uracil group was demonstrated to be a 
pharmacophore of CYN,12 likely facilitating direct binding to nucleic acids and its further effects 
such as DNA strand breaks and other genotoxic effects36, all events usually accompanied by an 
imbalance in cellular ROS levels.37 It is however likely that other structures of CYN are also 
involved in its bioactivity. It remains so far unclear how CYN moves across the cellular 
membrane and which structures are crucial in this process6. It was however, demonstrated that 
the sulfate group has no importance for this import process13. The role of the hydroxyl group in 
this matter is unknown. Interestingly, the naturally occurring 7-deoxy-cylindrospermopsin 3, that 
lacks the hydroxyl group, did not produce any toxic effects in an in vivo rodent model at levels 
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previously shown to exceed the lethal concentrations established for 13. Consistent with the 
conclusion that the hydroxyl group is important for cytotoxicity all active compounds in this 
study, 11a-11c and 1, contained this group. The 22 analogue, which is most closely related to 1 
in terms of its general structure and molecular weight, but lacks the hydroxyl group, did also not 
cause toxic outcomes. These findings support the view that the hydroxyl group may play an 
important role in the bioactivity of CYN and highlight the need for further studies focusing in 
detail on the mechanism of cellular uptake, intracellular localization and intracellular 
concentration of tested compounds. It should also be noted that exposure to 11a-11c analogues 
and 1 led to a more rapid onset of ROS production, indirectly indicating that their transport 
across the plasma membrane might be more efficient. Other compounds, such as cholesterol, 
are known to enter cellular membrane by inserting their hydroxyl group into hydrophilic 
phospholipid head group38. Therefore one hypothesis is that the -OH group at C-7 may be 
involved in the cellular transport of CYN possibly resembling the uptake of cholesterol. 
Moreover, it was established that CYN can be, at least partially, transported across the cellular 
membrane via passive diffusion owing to the low molecular weight and high hydrophilicity. The 
presence of –OH group in 1 and 11a-11c supports the hydrophilicity of those analogues due to 
the polarity of this functional group and likely increases the facilitated diffusion over this 
presented by 22 and GAA that lack it. As proposed, hydroxylation of C-7 is the last step of 
cyanobacterial biosynthesis of CYN and is catalyzed by a product encoded by cyrI gene of cyr 
cluster.19 This might also support the significance of –OH group in CYN bioactivity. Further 
studies are however necessary to elucidate the exact sequence of events in which hydroxyl 
group is involved in triggering the toxic potencies of CYN in eukaryotic cells. The present study 
did not find a linear association between toxicity and the length of tether. Since the greatest 
toxicity was found for the analogue 11c, which from the point of view of the proximity of the 
uracil, hydroxyl and guanidine groups, might be best able to adopt a similar conformation to that 
found in the naturally occurring compound 1.  
 
Conclusions  
 This study describes the synthesis of four CYN analogues differing in length of tether 
between guanidine and uracil groups, and the presence or absence of a hydroxyl group. The 
comparison of bioactivity of the synthetic analogues revealed that only those having a hydroxyl 
group at C-7 produced significant in vitro toxicity in human cells. The largest toxic effect was 
found in compound 11c, which has a 6-carbon tether separating the guanidine and uracil 
groups. This tether length might allow the molecule to adopt a similar conformation to that of 
CYN as might a 4-carbon tether as 11a had similar activity. The tether length of 5-carbons gave 
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an appreciably lower activity. Overall the present study adds to the general understanding that 
CYN damages human tissue by increasing oxidative stress levels which in turn damages 
membrane lipids and can trigger cell death. The results also highlight the potentially important 
role of the hydroxyl group at C-7 in cellular uptake and toxicity. Further studies on detailed 
mechanism of cellular uptake, intracellular localization and intracellular concentration are 
required to fully elucidate these points.  
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Experimental 
All glassware used was washed with acetone and dried with N2 or in a vacuum oven. Reagents 
and starting materials were from commercial suppliers and used as supplied. Diethyl ether and 
tetrahydrofuran were distilled from benzophenone and sodium wire, whilst dichloromethane was 
dried over CaH and freshly distilled. Dry DMF and methanol were purchased from Aldrich. 
Petroleum ether (PE) refers to the fraction distilled between boiling range of 40-60 ºC. Column 
chromatography and TLC chromatography was carried out using silica and silica plates 
purchased from Fluorochem Ltd (particle size 35-70 ) using HPLC grade acetic acid (AA) 
chloroform (CFM), dichloromethane (DCM), diethyl ether (DE), ethyl acetate (EA), hexane (HX) 
and methanol (ME). Compounds were visualized using UV, iodine or stained using 
polyphosphomolybdic acid (PMA) in EtOH or vanillin in EtOH/H2SO4, with heating. IR spectra 
were recorded on a Perkin-Elmer 1600 series FTIR instrument as KBr discs, thin films, Nujol 
mulls, or chloroform solution on NaCl plates with absorption frequencies reported in 
wavenumbers (cm-1). Routine NMR samples were performed on a Bruker AC250, AC400 or on 
a Bruker Avance-500 spectrometer. Chemical shifts for spectra are all reported in  values 
(ppm) relative to the residual solvent peak in each case. Electron Ionisation (EI) and Chemical 
Ionisation (CI) mass spectra were recorded on an Agilent Tech. 6890N spectrometer or an 
XCalibur MAT900 XLT spectrometer and ESI were recorded on a LTQ Orbitrap XL at the 
EPSRC Mass Spectrometry Service (Swansea). 
 
General method for the Grignard reaction. 
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A solution of EtMgBr in THF (1M, 1.9 eqv.) was added to a stirred and cooled (0 °C) 
solution of the alkyne 13 (2 eqv.) in dry THF (2.5 mL per mmol of 13) and the resulting mixture 
was stirred for 1 h. This solution was then added via cannula to a cooled (-78 °C) solution of 
aldehyde 12 (1.0 eqv) in dry THF (4 mL per mmol of 12) and the mixture stirred for 2 h. After 
warming to rt overnight NH4Cl solution (aqueous, saturated, 20 mL) was added and the mixture 
extracted with EA (3 × 50 mL) and the combined organic extracts washed with brine (25 mL) 
and water (25 mL), dried (MgSO4|) and evaporated under reduced pressure. The crude residue 
was purified by flash chromatography on silica gel (EA/PE 5-30%) to give the acetylinic alcohols 
14a-c as unstable oils.  
4-((tert-Butyldimethylsilyl)oxy)-1-(2,6-dimethoxypyrimidin-4-yl)but-2-yn-1-ol 14a: 75 %; Rf 
0.32 (25% EA/PE); H 0.09 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH3), 1.95 (1H, br s, OH), 3.97 
(3H, s, CH3), 3.99 (3H, s, CH3), 4.35 (2H, d J 1.1 Hz, CH2), 5.31 (1H, t, J 1.1 Hz, CH), 6.54 (1H, 
s, CH); C -5.1, 18.4, 25.9, 51.8, 54.3, 55.1, 63.3, 82.8, 85.1, 98.2, 165.2, 168.7, 172.5; vmax 
3392, 2955, 2930, 2885, 2858, 1597, 1572, 1484, 1463, 1382, 1358, 1255, 1203, 1129, 1059, 
815, 779; m/z (CI) 339.2 (100%, [M+H]+), 577.2 (90%, [2M+H]+); HRMS (CI) C16H27N2O4Si 
([M+H]+) requires 339.1735, found 339.1735.  
5-((tert-Butyldimethylsilyl)oxy)-1-(2,6-dimethoxypyrimidin-4-yl)pent-2-yn-1-ol 14b: 71 %; 
Rf 0.32 (25% EA/PE); H 0.04 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH3), 2.45 (2H, dt, J 2.0, 7.1 Hz, 
CH2) 3.72 (2H, t, J 7.1 Hz, CH2), 3.90 (1H, br s, OH) 3.99 (3H, s, CH3), 4.01 (1H, s, CH), 5.27 
(1H, br t, J 2.0 Hz, CH), 6.56 (1H, s, CH); C  -5.2, 18.4, 23.3, 26.0, 54.3, 55.2, 61.7, 63.3, 79.2, 
84.5, 98.2, 165.1, 169.1, 172.6; vmax 3384, 2953, 2929, 2883, 2857, 1596, 1572, 1482, 1462, 
1381, 1356, 1253, 1203, 1102, 1056, 836, 777; m/z (CI) 339.2 (100%, [M+H]+), 577.2 (90%, 
[2M+H]+) HRMS (CI) C17H28N2O4Si ([M+H]+) requires 353.1890, found 353.1891. 
6-((tert-Butyldimethylsilyl)oxy)-1-(2,6-dimethoxypyrimidin-4-yl)hex-2-yn-1-ol 14c: 55 %; Rf 
0.34 (25% EA/PE); H 0.00 (6H, s, 2 × CH3), 0.84 (9H, s, 3 × CH3), 1.69 (2H, tt, J 6.0, 7.1 Hz, 
CH2), 2.29 (2H, dt, J 2.0 Hz, CH2), 3.63 (2H, t, J 6.0 Hz, CH2), 3.90 (1H Br s OH), 3.95 (3H, s, 
CH3), 3.98 (3H, s CH3), 5.25 (1H, br t, J 2.0 Hz, CH), 6.54 (1H, s, CH); C  -5.3, 15.3, 26.0, 31.5, 
54.2, 55.0, 61.6, 63.5, 78.3, 87.0, 98.0, 165.1, 169.5, 172.5; vmax 3434, 2955, 2930, 2897, 2858, 
2216, 1590, 1570, 1483, 1463, 1386, 1360, 1253, 1203, 1100, 1056, 836, 758; m/z (CI) not 
determined (unstable to oxidation). 
 
General method for hydrogenation. 
Palladium on activated carbon (1:1 by mass with 14) was added to a solution of alkyne 
14 (1.0 eqv.) in EA (4 mL per mmol) under an argon blanket. The flask was purged with 
hydrogen gas (balloon) and the mixture stirred vigorously under a hydrogen atmosphere for 2 h. 
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The mixture was then filtered through a Celite© pad which was washed with further portions of 
EA and the filtrate concentrated by evaporation under reduced pressure. The crude product was 
purified by column chromatography on silica gel (10-40% EA/PE) to give the alkanes 15a-c as 
colourless oils.  
4-((tert-Butyldimethylsilyl)oxy)-1-(2,6-dimethoxypyrimidin-4-yl)butan-1-ol 15a: 79 %; Rf 
0.25 (20% EA/PE); H 0.05 (6H, s, 2 × CH3), 0.89 (9H, s, 3 × CH3), 1.60-1.78 (3H, m, CH, CH2), 
1.93-2.03 (1H, m, CH), 3.65 (2H, t, J 6.5 Hz, CH2), 3.95 (3H, s, Me), 3.97 (3H, s, Me), 4.13 (1H, 
br s, OH), 4.56 (1H, m, CH), 6.44 (1H, s, CH); C 5.3, 18.4, 26.0, 28.6, 34.7, 54.0, 54.8, 63.4, 
72.7, 97.5, 165.1, 172.3, 174.2; vmax 3402, 2955, 2930, 2885, 2857, 1598, 1570, 1481, 1462, 
1382, 1355, 1255, 1203, 1153, 1097, 1006, 836, 776; m/z (CI) 343.2 (100%, [M+H]+), 365.2 
(15%, [M+Na]+), 707.4 (30%, [2M+Na]+); HRMS (CI) C16H31N2O4Si ([M+H]+) requires 343.2048, 
found 343.2049. 
5-((tert-butyldimethylsilyl)oxy)-1-(2,6-dimethoxypyrimidin-4-yl)pentan-1-ol 15b: 100 %; Rf 
0.27 (20% EA/PE); H 0.00 (6H, s, 2 × CH3), 0.85 (9H, s, 3 × CH3), 1.39-1.58 (4H, m, 2 x CH2), 
1.61-1.70 (1H, m, CH), 1.74-1.83 (1H, m, CH), 3.37 (1H, br s, OH), 3.52 (2H, t, J 6.3 Hz, CH2), 
3.94 (3H, s, Me), 3.97 (3H, s, Me), 4.53 (1H, dd, J 4.6, 7.6 Hz, CH2) 6.32 (1H, s, CH); C -5.2, 
18.4, 21.6, 26.0, 32.6, 37.4, 54.1, 54.9, 63.1, 72.5, 97.5, 165.0, 172.2, 173.5; vmax 3422, 3018, 
2953, 2931, 2898, 2858, 1598, 1570, 1482, 1462, 1382, 1357, 1255, 1215, 1100, 1056, 1006, 
837, 758; m/z (CI) 357.2 (100%, [M+H]+), 735.4 (20%, [2M+Na]+); HRMS (CI) C17H33N2O4Si 
([M+H]+) requires 357.2204, found 357.2202. 
6-((tert-Butyldimethylsilyl)oxy)-1-(2,6-dimethoxypyrimidin-4-yl)hexan-1-ol 15c: 86 %; Rf 
0.34 (25% EA/PE); H 0.00 (6H, s, 2 × CH3), 0.86 (9H, s, 3 × CH3), 1.31-1.43 (4H, m, 2 x CH2), 
1.46-1.53 (2H, m, CH2), 1.60-1.69 (1H, m, CH), 1.73-1.81 (1H, m, CH), 3.47 (1H, br s, OH), 3.57 
(2H, t, CH2 J 6.3 Hz), 3.95 (3H, s, Me), 3.98 (3H, s, Me), 4.52 (1H, dd, J 4.6, 7.6 Hz, CH), 6.32 
(1H, s, CH); C -5.2, 18.5 (C), 25.0, 25.8, 32.8, 37.7, 54.1, 54.9, 63.2, 72.5, 97.4, 165.0, 172.2, 
173.5; vmax 3418, 2951, 2932, 2858,  1598, 1570, 1480, 1461, 1381, 1356, 1253, 1203, 1099, 
1056, 1006, 837, 758;  m/z (CI) 371.2 (100%, [M+H]+); HRMS (CI) C18H35N2O4Si ([M+H]+) 
requires 371.2361, found 371.2360. 
 
General method for acetylation. 
Acetic anhydride (3.7 eqv.) was added drop wise to a cooled (0˚C) and stirred mixture of 
the alcohol 15 (1.0 eqv.), pyridine (3.9 eqv.) and DMAP (0.1 eqv.) in dry DCM (10 mL per mmol 
of 15). The mixture was warmed to rt and stirred for 1 h, whereupon HCl (aqueous. 1 M, 10 
eqv.) was added and the mixture stirred for 30 min. The mixture was then extracted with DCM 
(3 x 25 mL) and the combined extracts washed with HCl (aqueous, 1M, 3 × 10 mL) and water 
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(20 mL). After drying (MgSO4) and evaporated under reduced pressure, column 
chromatography on silica gel (2.5-17.5% DE in PE) gave the acetates 16a-c as oils.  
1-(2,6-Dimethoxypyrimidin-4-yl)-4-((tert-butydimethylsilyl)oxy)butyl acetate 16a: 68 %; Rf 
0.28 (20% DE/PE); H 0.02 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH2), 1.51-1.62 (2H, m, CH2), 
1.84-1.94 (1H, m, CH), 1.96-2.04 (1H, m, CH), 2.13 (3H, s, CH3), 3.60 (2H, t, J 6.3 Hz, CH2), 
3.94 (3H, s, Me), 3.96 (3H, s, Me), 5.61 (1H, dd, J 4.8, 7.8 Hz, CH), 6.30 (1H, s, CH); C -5.2, 
18.4, 21.1, 26.0, 28.4, 30.6, 54.0, 54.9, 62.7, 75.2, 97.7, 165.4, 170.3, 170.6, 172.3; vmax 2956, 
2930, 2898, 2858, 2253, 1744, 1598, 1572, 1482, 1463, 1388, 1358, 1242, 1206, 1162, 1104, 
1059, 964, 910, 836; m/z (CI) 385.2 (100%, [M+H]+), 791.4 (15%, [2M+H]+), HRMS (CI) 
C18H33N2O5Si ([M+H]+) requires 385.2153, found 385.2146. 
1-(2,6-Dimethoxypyrimidin-4-yl)-4-((tert-butydimethylsilyl)oxy)butyl acetate 16b: 74 %; Rf 
0.64 (20% EA/PE); H 0.01 (6H, s, 2 × CH3), 0.86 (9H, s, 3 × CH2), 1.34-1.42 (2H, m, CH2), 
1.46-1.57 (2H, m, CH2), 1.80-1.98 (2H, m, CH2), 2.13 (3H, s, CH3), 3.57 (2H, t, J 6.3 Hz, CH2), 
3.94 (3H, s, Me), 3.96 (3H, s, Me), 5.58 (1H, dd, J 4.8, 7.8 Hz, CH), 6.30 (1H, s, CH); C -5.2, 
0.1, 18.5, 21.2, 21.6, 26.1, 32.6, 33.9, 54.0, 54.9, 62.9, 75.5, 97.7, 165.4, 170.4, 170.7, 172.3; 
vmax 2956, 2929, 2857, 1747, 1597, 1573, 1461, 1386, 1357, 1233, 1205, 1101, 837; m/z (CI) 
399.2 (100%, [M+H]+), 819.4 (10%, [2M+H]+); HRMS (CI) C19H35N2O4Si ([M+H]+) requires 
399.2310, found 399.2299. 
1-(2,6-Dimethoxypyrimidin-4-yl)-4-((tert-butydimethylsilyl)oxy)butyl acetate 16c: 88 %; Rf 
0.44 (20% EA/PE); H -0.02 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH2), 1.30-1.40 (4H, m, 2 x CH2), 
1.45-1.52 (2H, m, CH2), 1.79-1.97 (2H, m, CH2), 2.13 (3H, s, CH3), 3.57 (2H, t, J 6.3 Hz, CH2), 
3.95 (3H, s, Me), 3.97 (3H, s, Me), 5.58 (1H, dd, J 4.8, 7.8 Hz, CH), 6.30 (1H, s, CH); C -5.2, 
18.5, 21.2, 25.0, 25.7, 32.7, 34.2, 54.0, 54.9, 63.2, 75.4, 97.6, 165.4, 170.4, 170.7, 172.3; vmax 
2952, 2932, 2858, 1747, 1597, 1574, 1481, 1462, 1386, 1357, 1232, 1205, 1101, 1045, 835; 
m/z (CI) 413.2 (100%, [M+H]+); HRMS (CI) C20H37N2O5Si ([M+H]+) requires 413.2466, found 
413.2458. 
 
General method for silyl deprotection.  
A solution of TBAF (1M, 1.5 eqv.) in THF was added to a cooled (0˚C) solution of the 
silane 16 (1.0 eqv.) in THF (10 mL per mmol) and the resulting mixture stirred for 2 h. The 
reaction mixture was evaporated onto silica gel (ca 1-2 g per mmol of 16) under reduced 
pressure, then purified by flash chromatography on silica gel, (gradient elution; 30-40% EA/PE) 
to give 17a-c as colorless oils. 
1-(2,6-Dimethoxypyrimidin-4-yl)-4-hydroxybutyl acetate 17a: 80 %; Rf 0.26 (40% EA in 
PE); H 1.64-1.89 (4H, m, 2 × CH2), 2.00 (3H, s, CH3), 3.59 (1H, br s, OH), 3.94 (3H, s, CH3), 
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3.97 (3H, s, CH3), 4.04-4.11 (2H, m, CH2), 4.55 (1H, dd, J 2.6, 6.3 Hz, CH), 6.33 (1H, s, CH); C 
21.0, 24.8, 34.0, 54.1, 54.9, 64.3, 72.0, 97.4, 165.1, 171.3, 172.3, 173.1; vmax 3440, 3428, 2955, 
2927, 1738, 1596, 1569, 1482, 1381, 1351; m/z (CI) 271.1 (100%, [M+H]+), 293.1 (40%, 
[M+Na]+), 563.2 (20%, [2M+Na]+); HRMS (CI) C12H19N2O5 ([M+H]+) requires 271.1288, found 
271.1287. 
1-(2,6-Dimethoxypyrimidin-4-yl)-4-hydroxybutyl acetate 17b: 74. %; Rf 0.26 (40% EA in 
PE); H 1.35-1.43 (2H, m, CH2), 1.49-1.62 (2H, m, CH2), 1.79-1.97 (2H, m, CH2) 2.11 (3H, s, 
CH3), 2.12 (1H, br s, OH), 3.57 (2H, t, J 6.5 Hz, CH2), 3.92 (3H, s, CH3), 3.94 (3H, s, CH3), 5.56 
(1H, dd, J 4.8, 7.5 Hz, CH), 6.28 (1H, s, CH); C 21.1,  21.4, 32.3, 33.8, 54.0, 54.9, 62.5, 75.2, 
97.5, 165.3, 170.4, 170.5, 172.2; vmax  3408, 2948, 2870, 1744, 1597, 1571, 1483, 1386, 1359; 
m/z (CI) 285.1 (100%, [M+H]+), HRMS (CI); C13H20N2O5 ([M+H]+) requires 285.1443, found 
285.1445. 
 1-(2,6-Dimethoxypyrimidin-4-yl)-6-hydroxyhexyl acetate 17c: 71 %; Rf 0.26 (40% EA in 
PE); H  1.27-1.39 (4H, m, 2 x CH2), 1.49-1.56 (2H, m, CH2), 1.78-1.95 (3H, m, CH2, OH), 2.12 
(3H, s, CH3), 3.58 (2H, t, J 6.6 Hz, CH2), 3.93 (3H, s, CH3), 3.95 (3H, s, CH3), 5.56 (1H, dd, J 
4.9, 7.8 Hz, CH), 6.28 (1H, s, CH); C 21.1, 21.9, 25.5, 32.5, 34.0, 54.0, 54.9, 62.7, 75.3, 97.5, 
165.3, 170.4, 170.6, 172.3; vmax  3414, 2934, 2862, 1746, 1598, 1573, 1483, 1386, 1358; m/z 
(CI) 299.2 (100%, [M+H]+), HRMS (CI) C14H23N2O5 ([M+H]+) requires 299.1601, found 
299.1599. 
 
General method for the guanylation, deprotection, reguanylation and purification. 
Guanylation: DIAD (1.5 eqv.) was added in a drop wise manner to a cooled (0 ˚C) and 
stirred solution of the alcohol 17 (1.0 eqv.), PPh3 (1.53 eqv.) and N,N′,N′′-tri-Boc-guanidine 18 (2 
eqv.) in dry THF (8 mL per mmol of 17). After stirring to rt overnight, water (3-4 eqv.) was added 
and the mixture stirred for 30 min after which the solution was evaporated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (5-20% EA/PE) 
to give 19a-c as gums, which were contaminated with quantities of DIAD byproducts and were 
used in the next step without further purification. Deprotection: Hydrochloric acid (6 mL per 0.1 
mmol, 0.5 M) was added to 19a-c (1.0 eqv.) and the mixture heated (100°C) at reflux for 16h. 
After cooling and evaporation under reduced pressure the residue was dried in a desiccator 
(P2O5) overnight, dissolved in ME (ca 2 mL) and DE (3-5 ml) was added to the cloud point 
whereupon an oily precipitate on cooling (-20˚C) overnight. This was found to be a mixture of 
11a-c and 20a-c. Reguanylation and ion exchange purification: The crude mixture from the 
previous step was dissolved in DMF (2-3 mL per 0.1 mmol) and 1H-pyrazole-1-carboxamidine 
hydrochloride (0.5-0.7 eqv) was added together with DIPEA (1.5-2.0 eqv) and the mixture 
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stirred at rt for 24 hrs. DE (5-10 ml) was added which resulted in the formation of an oily 
precipitate formed, whereupon the supernatant liquid was decanted. The precipitate was 
dissolved in ME (1-2 ml) and DE (3-5 ml) was added to the cloud point, and an oily precipitate 
formed on cooling (-20˚C) overnight. After decanting the supernatant liquid, the precipitate was 
dissolved in water (5 mL) then passed several times through a short column (3 g) of activated 
Amberlite© CG-50 (the resin was pre-washed with MeOH, then HCl (2 M), then water to pH = 
7). The column was then eluted with water (20 mL), ammonia (1 M (30 mL) and 2M (30 mL)), 
evaporation of the 2M ammonia washings gave on evaporation the crude guanidines 11a-c (the 
water fraction was found to contain residual product, which could be purified by repeating the 
Amberlite© CG-50 purification steps). The crude guanidine obtained was dissolved in ME (1-2 
ml) containing a drop of HCl (12 M) and DE (3-5 ml) was added to the cloud point. After cooling 
(-20˚C) overnight, the supernatant liquid was decanted to give 11a-c as gums after drying. 
1-(2,6-dimethoxypyrimidin-4-yl)-4-(1,2,3-tris(tertbutoxycarbonyl)guanidino)butyl acetate 
19a: Rf 0.26 (20% EA/PE); H 1.49 (18H, s, 6 × CH3), 1.50 (9H, s, 3 × CH3), 1.71-1.91 (2H, m, 
CH2), 2.04 (3H, s, CH3), 2.17-2.38 (2H, m, CH2), 3.94 (3H, s, CH3), 3.96 (3H, s, CH3), 4.11 (2H, 
t, J 6.4 Hz, CH2), 5.40-5.68 (1H, m, CH), 6.50 (1H, s, CH), 10.73 (1H, s, NH); C (partial data) 
21.1, 25.7, 27.9, 27.9, 28.1, 28.2, 54.0, 54.9, 61.1, 72.3, 99.1, 149.7, 152.5, 155.0, 170.8, 
172.2, 172.3 (5 x C not observed); m/z (CI) 612.3 (100%, [M+H]+), 1245.6 (90%, [2M+Na]+), 
312 (96%, [M-2Boc+H]+); HRMS (CI) C28H46N5O10 ([M+H]+) requires 612.3239, found 612.3225. 
1-(2,6-Dimethoxypyrimidin-4-yl)-5-(1,2,3-tris(tert-butoxycarbonyl)guanidino)pentyl acetate 
19b: Rf 0.26 (20% EA/PE); H 1.46 (9H, s, 3 × CH3), 1.49 (18H, s, 6 × CH3), 1.35-1.42 (2H, m, 
CH2), 1.59-1.73 (2H, m, CH2), 1.79-2.02 (2H, m, CH2) 2.14 (3H, s, CH3), 3.75 (2H, t, J 7.4 Hz, 
CH2), 3.95 (3H, s, CH3), 3.97 (3H, s, CH3), 5.58 (1H, dd, J 4.6, 7.7 Hz, CH), 6.30 (1H, s, CH), 
10.61 (1H, s, NH); C (partial data) 21.2, 22.5, 28.1, 28.1, 28.2, 28.6, 33.8, 47.7, 54.0, 54.9, 
75.4, 97.6,  149.6, 152.8, 153.6, 170.4, 170.6, 172.3 (5 x C not observed); m/z (CI) 626.3 (7%, 
[M+H]+), 648.3 (100%, [M+Na]+); HRMS (CI) C29H47N5O10Na ([M+Na]+) requires 648.3215, 
found 648.3221.  
 1-(2,6-Dimethoxypyrimidin-4-yl)-4-(1,2,3-tris(tertbutoxycarbonyl)guanidino)hexyl acetate 
19c: Rf 0.26 (20% EA/PE); H 1.26-1.36 (4H, m, 2 x CH2), 1.45 (9H, s, 3 × CH3), 1.47 (18H, s, 6 
× CH3), 1.55-1.66 (2H, m, CH2), 1.77-1.92 (2H, m, CH2), 2.13 (3H, s, CH3), 3.72 (2H, t, J 7.5 Hz, 
CH2), 3.95 (3H, s, CH3), 3.96 (3H, s, CH3), 5.55 (1H, dd, J 4.8, 7.7 Hz, CH), 6.27 (1H, s, CH), 
10.59 (1H, s, NH); C (partial data) 21.1, 24.9, 26.6, 28.1, 28.1, 28.2, 28.7, 34.1, 47.9, 54.0, 





hydroxybutyl)amino)methaniminium chloride 11a: 54 % (over three steps); H (CD3OD) 1.59-
1.74 (2H, m, CH2), 1.76-1.86 (1H, m, CH2), 2.00-2.08 (1H, m, CH), 3.63 (2H, t, J 6.0 Hz, CH3), 
4.33 (1H, dd, J 3.8, 9.0 Hz, CH), 5.56 (1H, s, CH); c (CD3OD) 29.4, 31.8, 54.0, 61.8, 98.0, 
152.2, 157.1, 158.7, 166.8; m/z (CI) 242.1 (100%, [M]+); HRMS (CI) C9H16N5O3 ([M]+) requires 
242.1248, found 242.1250. 
Amino((5-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-5-
hydrooxypentyl)amino)methaniminium chloride 11b: 12 % (over three steps); H (CD3OD) 1.42-
1.80 (6H, m, 3 x CH2), 3.19 (2H, t, J 7.0 Hz, CH2), 4.38 (1H, dd, J 4.5, 7.6 Hz, CH), 5.63 (1H, s, 
CH); c (CD3OD) 23.3, 29.6, 36.5, 42.3, 70.2, 97.3, 153.4, 158.6, 161.6, 167.4; m/z (CI) 256.1 
(100 %, [M]+); HRMS (CI) C10H18N5O3 ([M]+) requires 256.1404, found 256.1411. 
Amino((5-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-6-
hydrooxypentyl)amino)methaniminium chloride 11c: 23 % (over three steps); H (CD3OD) 1.37-
1.76 (8H, m, 4 x CH2), 3.17 (2H, t, J 7.0 Hz, CH2), 4.36 (1H, dd, J 4.8, 7.2 Hz, CH), 5.62 (1H, s, 
CH); c (CD3OD) 25.8, 27.4, 29.7, 36.9, 42.4, 70.4, 97.3, 153.4, 158.6, 161.8, 167.4; m/z (CI) 
270.2 (100 %, [M]+); HRMS (CI) C10H18N5O3 ([M]+) requires 270.1561, found 270.1557. 
 
Allyl (5aR,8aS)-4-((1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl)- 
3,5a,6,7,8,8a-hexahydro-1H-2,2a1,3-triazaacenaphthylene-5-carboxylate acetate 25.  
A solution of aldehyde 2316,17 (255.1 mg, 0.719 mmol) in AA (3 mL) was stirred at rt for 
24 h. After evaporation under reduced pressure, residual AA was removed by co-evaporation 
with CFM (3 x 15 mL) and the residue dried under high vacuum for 4 h. The resultant salts 
where dissolved in trifluoroethanol (1.5 mL) and morpholine acetate (264.7 mg, 1.798 mmol), 24 
(1.55 g, 3.595 mmol) and anhydrous sodium sulphate (1.0 g) were added and the resultant 
mixture stirred at 70°C in a sealed Carius tube for 12 d. After cooling to rt and evaporation, 
purification was achieved by flash column chromatography on silica gel using ME/CFM 
(stepwise gradient of 1% increments 0:100 to 8:92) containing 1% AA. Fractions eluting in 5:95 
ME/CFM gave 25 as a tan oil (82.5 mg, 0.135 mmol, 19%). Rf 0.53 (10% ME/CFM); H 1.36-
1.41 (2H, m, 2 x CH), 1.52-1.64 (3H, m, 3 x CH), 1.78-1.81 (2H, m, 2 x CH), 1.96 (3H, s, CH3), 
3.19 (1H, dd, J = 9.6, 1.3 Hz, CH2), 3.54-3.58 (1H, m, CH), 3.79 (1H, d, J = 16.6 Hz, CH2), 3.83-
3.88 (1H, m, CH), 3.98 (1H, d, J = 16.6 Hz, CH2), 4.40 (1H, dd, J = 11.2, 2.4 Hz, CH), 4.46-4.48 
(2H, m, CH2), 5.09-5.22 (6H, m, 3 x CH2), 5.82 (1H, ddt, J = 16.1, 10.8, 5.6 Hz, CH), 7.17-7.37 
(10H, m, 10 x CH); C (partial data) 21.8, 22.5, 30.2, 31.8, 39.1, 45.5, 47.3, 48.9 (HSQC), 54.2, 
58.5, 65.5, 101.0, 103.0, 118.2, 127.4, 128.5, 128.6, 129.3, 129.4, 129.8, 133.9, 137.6, 138.3, 
154.0, 156.5, 159.8, 164.6, 166.8 (1 x C not observed); vmax 3064, 3010, 2957, 2928, 2856, 
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1700, 1659, 1617, 1562, 1496, 1449, 1395, 1361, 1314, 1248; m/z (ESI) 1103 (16%, [2M+H]+), 
574 (14%, [M+Na]+), 552 (100%, [M+H]+); m/z (ESI negative) 121 (100), 75 (88), 59 (85%, [M-
H]-); HRMS (ESI) C32H34N5O4 [M+H]+ requires 552.2605, found 552.2602. 
 
1,3-Dibenzyl-6-(((4R,5aR,8aS)-3,4,5,5a,6,7,8,8a-octahydro-1H-2,2a1,3-triazaacenaphthylen-4-
yl)methyl)pyrimidine-2,4(1H,3H)-dione acetate 26. 
Tetrakis(triphenylphosphine)palladium(0) (8.1 mg, 0.007 mmol) and pyrrolidine (0.027 
mL, 0.337 mmol) were added to a stirred solution of 25 (206.0 mg, 0.337 mmol) in a 1:1 mixture 
of anhydrous ME/THF (6 mL). The reaction was stirred at rt and progress monitored by TLC. 
After 4 h the solvent was removed under reduced pressure and the residue dissolved in ME (3 
mL) and AA (3 mL) and cooled (0 °C), whereupon sodium cyanoborohydride (105.8 mg, 1.685 
mmol) was added and the mixture stirred to rt over 16 hours. After evaporation, the reaction 
material was purified by flash column chromatography on silica gel using ME/CFM (0:100 to 
15:85) containing 1% AA. Fractions eluting in 10:90 ME/CFM gave 26 (133.8 mg, 0.253 mmol, 
75%) as a pale yellow oil. Rf 0.18 (10% ME/CFM); H 0.95-1.10 (2H, m, 2 x CH), 1.17-1.26 (1H, 
m, CH2), 1.32-1.42 (1H, m, CH2), 1.77-1.81 (1H, m, CH2), 1.85-1.89 (1H, m, CH2), 1.94 (3H, s, 
CH3), 1.97-2.01 (1H, m, CH2), 2.03-2.07 (1H, m, CH2), 2.45 (1H, dd, J = 9.9, 2.7 Hz, CH2), 2.98-
3.03 (1H,  m, CH), 3.12-3.20 (2H, m, 2 x CH), 3.40-3.45 (1H, m, CH), 3.52-3.60 (1H, m, CH), 
3.73-3.78 (1H, m, CH2) 4.94-5.37 (4H, m, 2 x CH2), 5.64 (1H, s, CH), 7.16-7.49 (10H, m, 10 x 
CH); C 22.0, 23.3, 29.5, 30.9, 34.2, 36.9, 44.7, 47.7, 47.9, 48.5, 49.6, 56.7, 102.7, 126.4, 127.6, 
127.8, 128.3, 129.0, 129.0, 136.0, 136.6, 150.7, 152.6, 155.6, 161.8, 178.0; vmax 3155, 3065, 
3034, 2947, 2931, 2862, 1704, 1668, 1620, 1586, 1557, 1497, 1451, 1398, 1340 and 1262; m/z 
(ESI) 470 (100%, [M+H]+); m/z (ESI negative) 157 (18), 141 (20), 121 (100), 75 (86), 73 (12), 
59 (83%, [M-H]-); HRMS (ESI) C28H32N5O2 [M+H]+ requires 470.2551, found 470.2546. 
 
6-(((4R,5aR,8aS)-3,4,5,5a,6,7,8,8a-Octahydro-1H-2,2a1,3-triazaacenaphthylen-4-
yl)methyl)pyrimidine-2,4(1H,3H)-dione hydrobromide 22.  
Boron tribromide (106 µL, 1.120 mmol) was added to a stirred solution of 26 (118.4 mg, 
0.224 mmol) dissolved in xylenes (12 mL) and the mixture heated at reflux for 16 h. On cooling 
to rt ME (5 mL) was slowly added and the mixture stirred for a further 16 h. After evaporation, 
the crude product was purified by flash column chromatography on silica gel (ME:CFM (0:100 to 
30:70 containing 1% AA). Fractions eluting in 12:88 ME/CFM gave 22 (77.9 mg, 0.210 mmol, 
94%) as a waxy solid. Rf 0.11 (20% ME/CFM); H 1.21-1.29 (1H, m, CH2), 1.33-1.41 (1H, m, 
CH2), 1.47-1.56 (2H, m, 2 x CH), 1.93-1.99 (2H, m, 2 x CH), 2.06-2.09 (1H, m, CH2), 2.29 (1H, 
dt, J = 13.5, 3.6 Hz, CH2), 2.69 (2H, d, J = 6.8 Hz, CH2), 3.18-3.25 (1H, m, CH2), 3.40 (1H, tt, J 
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= 10.9, 3.6 Hz, CH), 3.80-3.86 (3H, m, 3 x CH), 5.59 (1H, s, CH); C 23.1, 30.4, 31.7, 35.1, 38.3, 
49.3, 49.6, 51.2, 58.3, 101.8, 153.3, 153.4, 156.4, 166.8; vmax 3322, 3159, 3054, 2963, 2927, 
2859, 1713, 1659, 1607, 1445, 1342, 1331; m/z (ESI) 579 (4%, [2M+H]+), 394 (5), 372 (10), 312 
(9%, [M+Na]+), 290 (100%, [M+H]+); m/z (ESI negative) 125 (53), 85 (27), 81 (95), 79 (100%, 
[M-H]-), 62 (20), 32 (21); HRMS (ESI) C14H20N5O2 [M+H]+ requires 290.1612, found 290.1607. 
 
1,3-Dibenzylurea 27.18  
A vigorously stirred suspension of finely powdered carbohydrazide (9.0 g, 100.0 mmol) in 
DMF (200 mL) and benzylamine (109 mL, 1000 mmol) was cooled to 0 °C, to which I2 (100.0 g, 
0.40 mol) was added in portions over 1 h until a brown colour persisted. Excess Iodine was 
removed by the addition of Na2S2O3 (Sat, ca. 2-3 mL) and the desired compound was 
precipitated from the resulting straw yellow solution by the addition of water (800 mL). After 
filtration and drying under vacuum, 27 (15.3 g, 64 mmol, 64%) was obtained as a white solid 
which was used without further purification. Recrystallisation from THF/toluene gave An 
analytically pure of sample. Rf  0.20 (50% EA/PE); Mp 165-168 °C (lit.39 168-169 °C); H 4.23 
(2H, s, CH2), 4.24 (2H, s, CH2), 6.43 (2H, t, J = 5.8 Hz, 2 x NH), 7.20-7.33 (10H, m, 10 x CH); C 
43.0, 43.0, 126.5, 127.0, 128.2, 140.9, 158.1; vmax 3337, 3086, 3062, 3030, 2919, 2874, 1627, 
1613, 1589, 1574, 1493, 1472, 1453, 1421; m/z (ESI) 503.2 (25%, [2M+Na]+), 481.3 (100%, 
[2M+H]+), 263.1 (8%, [M+Na]+), 241.1  (95%, [M+H]+); HRMS (ESI) C15H17N2O [M+H]+ requires 
241.1335, found 141.1333. 
  
Ethyl 2-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetate 29. 
Urea 27 (11.5 g, 47.7 mmol), diethyl 1,3-acetonedicarboxylate 28 (17.3 mL, 95.4 mmol) 
and p-TsOH (907 mg, 4.8 mmol) were dissolved in benzene (250 mL) and the mixture heated to 
reflux under a soxhlet extractor containing powdered 4 Å molecular sieves (ca 20 g). The 
molecular sieves were replaced every 2 days and after 4 days 1H NMR analysis indicated 
complete consumption of the starting material. The reaction mixture was cooled to rt, diluted 
with DCM (800 mL) and washed with NaHCO3 (sat. 3 x 150 mL) and brine (100 mL). After 
drying and evaporation the resulting viscous oil was stirred with PE (300 mL). After 1 hour the 
solvent was decanted and the resultant precipitate triturated with DE (4 x 100 mL) to give ester 
29 as a pale yellow solid (12.1 g, 32.0 mmol, 67%). Rf 0.41 (50% EA/PE); Mp 119-122 °C; H 
1.26 (3H, t, J 7.2 Hz, CH3), 3.4 (2H, s, CH2), 4.14 (2H, q, J 7.2 Hz, CH2), 5.13 (2H, s, CH2), 5.17 
(2H, s, CH2), 5.73 (1H, s, CH), 7.11-7.50 (10H, m, 10 x CH); C 14.0, 38.7, 44.8, 48.1, 62.2, 
104.3, 126.1, 127.6, 127.9, 128.4, 129.0, 129.1, 135.8, 136.7, 147.7, 152.5, 161.8, 167.4; vmax 
3090, 3061, 3023, 3008, 2979, 2935, 1738, 1702, 1693, 1654, 1662, 1617, 1584, 1495, 1451, 
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1423, 1396, 1367, 1333; m/z (ESI) 779.3 (6%, [2M+Na]+), 757.3 (100%, [2M+H]+), 401.1 (5%, 
[M+Na]+), 379.2 (95%, [M+H]+); HRMS (ESI) C22H23N2O4 [M+H]+ requires 379.1652, found 
379.1650. 
 
2-(1,3-Dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetic acid 30.  
Sodium hydroxide (2.25 g, 56.1 mmol) was added to a cooled (0 °C), stirred suspension 
of ester 29 (10.62 g, 28.1 mmol) in ethanol (500 mL) and the mixture stirred to rt over 5 d. The 
mixture was quenched with H2O (600 mL) and the pH adjusted to pH 1-2 by the slow addition of 
1 M HCl, then extracted with DCM (3 x 100 mL) and the combined organic extracts dried over 
magnesium sulfate. After evaporation the resulting pale brown solid was triturated with DE (3 x 
70 mL) to give acid 30 as an off white solid (7.70 g, 22.0 mmol, 78%). Rf 0.26 (20% ME/DCM); 
Mp 138-141 °C; H 3.57 (2H, s, CH2), 5.02 (2H, s, CH2), 5.04 (2H, s, CH2), 5.88 (1H, s, CH), 
7.15-7.36 (10H, m, 10 x CH), 13.07 (1H, s, COOH); C 38.0, 43.8, 47.5, 103.0, 125.9, 127.2, 
127.4, 127.6, 128.4, 128.7, 136.4, 137.0, 149.6, 152.0, 161.3, 169.4; vmax 3442, 3096, 3063, 
3034, 2921, 2793, 2695, 2576, 1722, 1705, 1693, 1642, 1598, 1496, 1472, 1454, 1423, 1399, 
1367, 1351, 1315; m/z (ESI) 701.3 (100%, [2M+H]+), 373.1 (15%, [M+Na]+), 351.1 (100%, 
[M+H]+); HRMS (ESI) C20H19N2O4 [M+H]+ requires 351.1399, found 351.1340. 
 
Allyl 4-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3-oxobutanoate 24. 
Pyrimidine 30 (1.50 g, 4.28 mmol), Meldrum's acid 31 (0.68 g, 4.71 mmol) and CDI (1.04 
g, 6.42 mmol) were dissolved in THF (20 mL) and the mixture heated at 50 °C for 16 h. Upon 
cooling to rt the solvent was removed under reduced pressure and the residue diluted with 
DCM/H2O (1:1, 160 mL) and the pH of the aqueous layer adjusted to pH 2 by the slow addition 
of 1 M HCl. The organic layer was then separated and washed with H2O (50 mL), dried over 
magnesium sulfate and the solvent removed under vacuum. The resulting yellow solid was 
dissolved in allyl alcohol (20 mL) and the mixture heated at 110 °C for 16 h. After cooing the 
mixture was evaporated under reduced pressure and the resulting material purified by flash 
column chromatography on silica gel using EA/PE (15:85 to 30:70). Fractions eluting in 25:75 
EA/PE gave 24 as a viscous yellow oil (1.38 g, 3.19 mmol, 75%). Rf 0.08 (30% EA/PE); H 3.77 
(2H, s, CH2), 3.98 (2H, s, CH2), 4.58 (2H, dt, J 5.5, 1.4 Hz, CH2), 4.69 (2H, s, CH2), 5.02 (2H, s, 
CH2), 5.19-5.33 (2H, m, CH2), 5.81 (1H, s, CH), 5.83-5.92 (1H, m, CH), 7.14-7.36 (10H, m, 2 x 
Ph); C 43.8, 46.1, 47.6, 48.2, 65.2, 103.2, 118.3, 126.0, 127.3, 127.4, 127.5, 128.4, 128.7, 
132.1, 136.6, 137.1, 149.3, 151.9, 161.2, 166.6, 198.4; vmax 3094, 3067, 3023, 3002, 2968, 
2939, 1746, 1727, 1705, 1702, 1663, 1628, 1586, 1497, 1453,1396, 1347 and 1328; m/z (ESI) 
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865.3 (50%, [2M+H]+), 455.2 (6%, [M+Na]+), 433.2 (100%, [M+H]+); HRMS (ESI) C25H25N2O5 
[M+H]+ requires 433.1758, found 433.1756. 
 
Toxicological studies: The toxicity of CYN variants was evaluated using human neutrophils in 
an in vitro model. Heparinized blood samples (6.0 mL) were collected in lithium heparin tubes 
from 3 healthy (screened by physical examination, medical history and initial blood tests), non-
smoking and normal weighted (BMI 18.5–24.9) male donors (aged 21–25 years old) at the 
Regional Centre of Blood and Blood Treatment in Poznan, Poland, according to accepted 
safeguard standards and legal requirements. Human neutrophils were isolated immediately 
after collection using a one-step density-gradient centrifugation on Gradisol G of a specific 
gravity of 1.115 g mL-1 (Polfa, Poland) at 400 g at room temperature for 30 min. The residual 
erythrocytes were removed from the cell population by hypotonic lysis. The purity of the 
neutrophils (>90%) was verified by counting under a light microscope after May-Grunwald-
Giemsa staining. Neutrophils were exposed for 1 h to 2.0 µg/mL of 11a-c, 22, 1 or GAA and 
their toxicity was compared by monitoring the intracellular generation of reactive oxygen species 
(ROS), peroxidation of lipids and cell survival. Each experimental assay was performed on three 
independent neutrophil isolates with three technical replicates. The negative control was 
constituted of unexposed cells. The positive control was constituted of cells exposed to 10 µM 
tert-butyl hydroperoxide (tBHP), a well established inducer of oxidative stress and specifically, 
lipid peroxidation and oxidative stress-induced death in eukaryotic cells. 
 
Intracellular reactive oxygen species assay: Human neutrophils were loaded for 30 min at 37 
C in darkness with 20 M of 2’,7’ –dichlorofluorescin diacetate (DCFDA; Abcam, UK), a 
fluorogenic dye that measures hydroxyl, peroxyl and other reactive oxygen species (ROS) 
activity within the cell. Cells were then washed, dissolved in PBS, seeded in a black clear 
bottom 96-well plate at a density of 20 x 104 neutrophils per well (90 μL aliquots/well) and 
exposed to tested compounds for 1h at 37C for 1 h. Fluorescence of DCFDA was measured 
kinetically after 5, 15, 30, 45 and 60 min of incubation using a Synergy HTX multi-mode plate 
reader (BioTek, USA) at an excitation of 495 nm and emission of 528 nm. The background 
signal, measured in exposed neutrophils not loaded with DCFDA, was withdrawn from the 
corresponding samples. The final results were presented as a percentage of the negative 
control.  
 
Lipid peroxidation assay: Lipid peroxidation was analyzed using a Lipid Peroxidation 
Colorimetric/Fluorometric Assay Kit (BioVision, UK) by means of malondialdehyde (MDA) 
22 
 
content. Human neutrophils were seeded in a 96-well plate at a density of 20 x 104 neutrophils 
per well (90 μL aliquots/well) and exposed to each tested compound for 1 h at 37 C. The 
control was constituted of cells incubated with 10 μL of PBS. After the experiments, cells were 
harvested from each well and homogenized on ice in 300 μL of provided lysis buffer and 
centrifuged to remove insoluble material. The resulting 200 μL of supernatants were transferred 
to a microcentrifuge tube and supplemented with 600 μL of thiobarbituric acid (TBA) to generate 
an MDA–TBA adduct. To accelerate the reaction, samples were incubated at 95 °C for 60 min 
and the final product was measured colorimetrically at 532 nm. The calculated values were 
compared to a calibration curve prepared using MDA standard (BioVision, UK). The coefficient 
of variation (r2) for the calibration curve was 0.99. The final results were presented as a 
percentage of the negative control. 
 
Cell viability assay: Cell viability was determined using the colorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5 diphenyltetrazolium bromide (MTT) metabolic activity assay (BioVision, UK). Human 
neutrophils were seeded in a 96-well plate at a density of 20 x 104 neutrophils per well (90 μL 
aliquots/well) and exposed to each tested compound for 1 h at 37 °C. Afterwards, cells were 
washed, seeded again, and 10 µL of MTT was added to each well for 3 h. Neutrophils were 
then treated with 10% sodium dodecyl sulfate in 0.01 M HCl and incubated for another 6 h in 
the darkness to dissolve formazan crystals. The optical density (OD) of the final product (the 
formazan crystals) was measured at 570 nm using a Synergy HTX microplate reader (BioTek, 
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